News Focus
News Focus
icon url

runncoach

06/01/20 7:48 PM

#16134 RE: Investor2014 #16133

Has nothing to do of course with how many patients improved in the trials or the fact that anavex showed zero success in patients with mmse scores below 20. Apparently it can "restore homeostasis" in roughly 5% of the population lol. Quite the MOA. What percentage of patients who improve would one consider a trial a success?
icon url

DRK123

06/01/20 8:54 PM

#16135 RE: Investor2014 #16133

Reminder to us all—

Not all clinical trials are created equal, at least in the clinical arena fighting Alzheimer’s

For example (it’s like)—

While the majority of Pharmaceuticals & Biotechs approach their trials simply trying to measure the square root of tau divided by the accumulation of plaque...

Neurotrope is using Calculus 3 to explore 3-dimensional limits approaching synaptic function, multiplied by projections of dendrites, bringing information flow back to the axons of mental capacity to increase dendritic branching of memory, though the scenario of “fight or flee” underneath the cannonball tree.

“We’re at the point where we love or hate it. We can write it down, or obliterate it.”